Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment
Open Access
- 31 December 2007
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 33 (8), 741-756
- https://doi.org/10.1016/j.ctrv.2007.07.018
Abstract
Drug resistance is a major problem in successful cancer chemotherapy. Many molecular mechanisms that are responsible for drug resistance are known whereas others have yet to be discovered. Determining the exact mechanism activated in a particular case (clinical or laboratory) is a difficult task. Recently, proteomics has been applied to investigate drug resistance mechanisms in model cancer cell lines. As a result, novel mechanisms of resistance have been discovered and known mechanisms of resistance confirmed. In this paper, we wish to review recent developments and progresses in the application of proteomic tools to identify known and novel drug resistance mechanisms in drug-selected model cancer cell lines. Our combined analyses of multiple proteomic studies of various drug resistant cancer cell lines revealed that many mechanisms of resistance likely exist in any given drug-selected cancer cell line and that common mechanisms of resistance may be selected in a spectrum of cancer cell lines. These observations suggest that combination therapies targeting multiple mechanisms to sensitize drug resistant cancers may be necessary to eradicate cancers in the future.Keywords
This publication has 77 references indexed in Scilit:
- A Platform for Accurate Mass and Time Analyses of Mass Spectrometry DataJournal of Proteome Research, 2007
- Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulinsInternational Journal of Cancer, 2007
- Identification of Platinum-Resistance Associated Proteins through Proteomic Analysis of Human Ovarian Cancer Cells and Their Platinum-Resistant SublinesJournal of Proteome Research, 2006
- Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1‐R10Proteomics, 2006
- A proteomic investigation into etoposide chemo‐resistance of neuroblastoma cell linesProteomics, 2005
- Distribution and significance of 14‐3‐3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissueThe Journal of Pathology, 2004
- Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell linesInternational Journal of Cancer, 2003
- MGr1-Ag is associated with multidrug-resistant phenotype of gastric cancer cellsGastric Cancer, 2002
- Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell deathExperimental & Molecular Medicine, 2002
- Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell linesEuropean Journal Of Cancer, 2000